Tarsus Pharmaceuticals Inc (TARS) Stock Price, Quote & News

Company Profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 409 1801

Website: www.tarsusrx.com

Address:

15440 Laguna Canyon Road, Suite 160, Irvine, United States

PrivateProfiteer Nov. 14 at 5:05 AM

$TARS is currently trading at $72.53, showing a strong upward momentum with an RSI of 65.33, indicating it is nearing overbought territory but still has room for further gains. The price is above both the 30-day moving average (MA30) of 70.08 and the 50-day moving average (MA50) of 64.03, suggesting bullish sentiment. The recent 60-day high of 76.81 provides a resistance level, while the low of 48.2 indicates a solid support base. Directional bias is bullish due to the price action above key moving averages and the RSI positioning. Suggested entry is at $73.00, with a stop loss at $70.00 to manage risk. Target 1 is set at $76.00, near the recent high, and Target 2 at $78.00, allowing for potential breakout gains. Monitor the ATR of 3.03 for volatility considerations. This plan leverages current strength while managing downside risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

Night_Owl_Biotech Nov. 13 at 9:36 PM

$CRMD Attached is a schedule of DefenCath product sales by quarter post launch versus like product sales post launch by quarter of 4 peer bios. DefenCath is outselling all 4 products by a comfortable margin yet CRMD's market cap is a fraction of all 4 peers. The column furthest to the right shows market cap as a multiple of Q6 product sales. As we read CRMD's Q3 2025 10Q, CRMD is generating gross margins north of 90% so it is not that. Can someone explain in simple English why CRMD is trading at such a lower valuation while outselling these 4 products? Our club looked at CRMD months ago but were put off by the Melinta acquisition as we lost a ton of money on PRTK back in the day. Any genuine guidance would be sincerely appreciated. It is understood total Q3 2025 CRMD sales were $104MM & CRMD has ~$150MM in debt FWIW we like all 4 peers $ARQT $TARS $AXSM & $TGTX. We're not questioning nor bashing their valuations. We simply want to understand the disconnect. TY This is not investment advice

3 · Reply

PrivateProfiteer Nov. 13 at 3:11 AM

$TARS: The last close at $75.64 indicates a strong position within the recent trading range, with the 60D high at $76.81 and the low at $48.2. The RSI of 66.82 suggests that the stock is approaching overbought territory, indicating potential for a pullback. However, the price is above both the 30-day MA of 69.04 and the 50-day MA of 63.39, which supports a bullish bias in the short term. Trade Plan: - Directional Bias: Bullish, but cautious due to high RSI. - Suggested Entry: $75.00 (anticipating a slight pullback). - Stop: $72.50 (below recent support). - Target 1: $78.00 (near the 60D high). - Target 2: $80.00 (psychological level). Monitor RSI for signs of reversal and adjust targets accordingly. https://privateprofiteers.com

0 · Reply

PrivateProfiteer Nov. 12 at 2:47 AM

0 · Reply

TickrTalk0007 Nov. 11 at 5:16 AM

$TARS this stock’s market cap makes ZERO sense…$3B market cap on $400M annual sales and $400M in annual SG&A…i have a feeling they are front running the sales…sg&a directly proportional to sales?

3 · Reply

CanadianSalmonGal_ Nov. 6 at 10:33 AM

$TARS coming back up soon , trust me

1 · Reply

IN0V8 Nov. 6 at 5:56 AM

$TARS Buy Oppenheimer raises target price to $95 from $75

0 · Reply

JarvisFlow Nov. 5 at 3:04 PM

Guggenheim updates rating for Tarsus Pharmaceuticals ( $TARS ) to Buy, target set at 84 → 87.

1 · Reply

Creyedr Nov. 5 at 1:56 PM

$VVOS $EVOK 100% Agree. Vivos is sitting on a goldmine. For me, this will be like $TARS .... 10x'd and still going because they met a treatment need that works for a common problem. Simple formula.

0 · Reply

SannieVerraderlijk Nov. 5 at 8:58 AM

$TARS Solid earnings again, hoping for 50's to get back in in case of broader sector drawdown

1 · Reply

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 10 days ago

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Oct 28, 2025, 5:00 PM EDT - 17 days ago

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Sep 26, 2025, 1:05 PM EDT - 7 weeks ago

Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off

Aug 27, 2025, 5:00 PM EDT - 2 months ago

Tarsus to Participate in Upcoming Investor Conferences

Aug 20, 2025, 8:46 AM EDT - 3 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff In August

PINC

Aug 7, 2025, 3:04 AM EDT - 3 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 3 months ago

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

Jul 30, 2025, 5:00 PM EDT - 3 months ago

Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

May 12, 2025, 12:28 PM EDT - 6 months ago

Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off

May 5, 2025, 6:27 AM EDT - 6 months ago

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

ELAN

May 1, 2025, 9:37 PM EDT - 7 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 7 months ago

Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

Apr 24, 2025, 5:00 PM EDT - 7 months ago

Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

$Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting$

Apr 22, 2025, 8:31 AM EDT - 7 months ago

Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting

Mar 12, 2025, 9:49 PM EDT - 8 months ago

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

Mar 12, 2025, 4:12 PM EDT - 8 months ago

Tarsus Announces Proposed $100.0 Million Public Offering

Mar 11, 2025, 12:36 PM EDT - 8 months ago

Tarsus Pharma: Strong Execution In Xdemvy Commercialization

Mar 6, 2025, 5:00 PM EST - 9 months ago

Tarsus to Participate in Upcoming Investor Conference

Feb 25, 2025, 6:01 PM EST - 9 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 5:00 PM EST - 9 months ago

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

Jan 13, 2025, 8:30 AM EST - 10 months ago

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

Dec 15, 2024, 2:00 PM EST - 11 months ago

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

SWTX

Nov 13, 2024, 10:23 PM EST - 1 year ago

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 8:30 AM EST - 1 year ago

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Nov 6, 2024, 4:30 PM EST - 1 year ago

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

Oct 17, 2024, 8:30 AM EDT - 1 year ago

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

Sep 25, 2024, 5:00 PM EDT - 1 year ago

Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024

Sep 20, 2024, 3:17 PM EDT - 1 year ago

Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations

Aug 28, 2024, 5:00 PM EDT - 1 year ago

Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference

Aug 20, 2024, 4:56 PM EDT - 1 year ago

Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment

Aug 10, 2024, 1:50 PM EDT - 1 year ago

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript

Jul 29, 2024, 4:30 PM EDT - 1 year ago

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

May 9, 2024, 5:00 PM EDT - 1 year ago

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

May 8, 2024, 9:45 PM EDT - 1 year ago

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:05 PM EDT - 1 year ago

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

May 1, 2024, 5:00 PM EDT - 1 year ago

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

Apr 23, 2024, 8:30 AM EDT - 1 year ago

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

Mar 7, 2024, 8:03 PM EST - 1 year ago

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tarsus to Participate at Upcoming Investor Conferences

Mar 5, 2024, 8:30 AM EST - 1 year ago

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Mar 1, 2024, 12:07 AM EST - 1 year ago

Tarsus Announces Pricing of $100.0 Million Public Offering

Feb 27, 2024, 12:09 PM EST - 1 year ago

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 6:00 AM EST - 1 year ago

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

Feb 22, 2024, 8:00 AM EST - 1 year ago

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

Feb 20, 2024, 5:00 PM EST - 1 year ago

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

Jan 31, 2024, 5:00 PM EST - 1 year ago

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

Dec 11, 2023, 8:00 AM EST - 2 years ago

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

Dec 5, 2023, 12:00 PM EST - 2 years ago

Celebrating Seeking Alpha's New Analysts - November 2023 Edition

AGNC CROX DPZ FHI GRPN GRVY GTN

PrivateProfiteer Nov. 14 at 5:05 AM

0 · Reply

Night_Owl_Biotech Nov. 13 at 9:36 PM

3 · Reply

PrivateProfiteer Nov. 13 at 3:11 AM

0 · Reply

PrivateProfiteer Nov. 12 at 2:47 AM

0 · Reply

TickrTalk0007 Nov. 11 at 5:16 AM

3 · Reply

CanadianSalmonGal_ Nov. 6 at 10:33 AM

$TARS coming back up soon , trust me

1 · Reply

IN0V8 Nov. 6 at 5:56 AM

$TARS Buy Oppenheimer raises target price to $95 from $75

0 · Reply

JarvisFlow Nov. 5 at 3:04 PM

Guggenheim updates rating for Tarsus Pharmaceuticals ( $TARS ) to Buy, target set at 84 → 87.

1 · Reply

Creyedr Nov. 5 at 1:56 PM

$VVOS $EVOK 100% Agree. Vivos is sitting on a goldmine. For me, this will be like $TARS .... 10x'd and still going because they met a treatment need that works for a common problem. Simple formula.

0 · Reply

SannieVerraderlijk Nov. 5 at 8:58 AM

$TARS Solid earnings again, hoping for 50's to get back in in case of broader sector drawdown

1 · Reply

Hawksssss Nov. 4 at 11:58 PM

$TARS forecasting20% growth for q4. That’s pretty good.

0 · Reply

perision Nov. 4 at 9:50 PM

$TARS looonngg term hold here…this is not penny stock mentality trade material loll

0 · Reply

Comicguy Nov. 4 at 9:48 PM

$TARS Musta been priced in.

0 · Reply

RonIsWrong Nov. 4 at 9:46 PM

$TARS

0 · Reply

RonIsWrong Nov. 4 at 9:45 PM

$TARS expecting $140-$145 M in Q4 annual rev $440 M - $445M

0 · Reply

RonIsWrong Nov. 4 at 9:41 PM

$TARS some snippets from the call

0 · Reply

lecorb Nov. 4 at 9:27 PM

$TARS Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.30 beats by $0.04, revenue of $118.7M beats by $3.X.48M

0 · Reply

RonIsWrong Nov. 4 at 9:22 PM

$TARS barely any trading going on

2 · Reply

DonCorleone77 Nov. 4 at 9:16 PM

$TARS Tarsus Pharmaceuticals reports Q3 EPS (30c), consensus (33c) -- Q3 revenue $118.7M, consensus $115.22M.

0 · Reply

RonIsWrong Nov. 4 at 9:10 PM

$TARS Tarsus Pharmaceuticals Q3 EPS $(0.30) Beats $(0.38) Estimate, Sales $118.697M Beat $115.222M Estimate

0 · Reply

YungBullHOLLA Nov. 4 at 9:07 PM

$TARS 🔥🔥🔥🔥

0 · Reply

RonIsWrong Nov. 4 at 9:07 PM

$TARS Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements Delivered quarterly XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial momentum

0 · Reply

Market Cap	3.18B
Revenue (ttm)	182.95M
Net Income (ttm)	-115.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-63.16%
Debt to Equity Ratio	0.22

Volume	253,662
Avg Vol	631,420
Day's Range	N/A - N/A
Shares Out	42.45M
Stochastic %K	63%
Beta	0.82
Analysts	Strong Sell
Price Target	$83.00